Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of ...

In conclusion, several Nifty 50 stocks, including Cipla, Sun Pharma and Infosys, experienced declines in Wednesday's trading ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection of the company's manufacturing facility in Bommasandra, Bengaluru as Voluntary ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Ciplas Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 1,778 crore, reflecting a 4% YoY ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.